In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
Cancer HealthCast
47m listen
An Intersectional Look at Anal Cancer and HIV
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.
-
Dr. Joel Palefsky Professor of Medicine University of California San Francisco -
Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Related Content
-
Labor CAIO Outlines Responsible and Ethical AI Priorities, Use Cases
Department of Labor Chief AI Officer Mangala Kuppa outlined how her role is shaping the agency’s artificial intelligence strategy.
20m watch -
Storytelling Miniseries: Mastering Mindful Communication with Elizabeth Barry
Join us as Elizabeth shares her unique approach to communication, offering tips and strategies for personal growth and leadership through storytelling.
17m listen -
VA Rolls Out Ride-Share Program With Uber
Veterans Health Administration Chief of Innovation Indra Sandal and Veterans Transportation Program Director Benjamin Williams discuss the program’s journey from pilot to live program.
26m listen -
Census Bureau Embraces Modernization, Data Innovation
Census Deputy Director and Chief Operating Officer Ron Jarmin outlines how the bureau is expanding its data collection, using AI to make Census staff more efficient and spearheading modernization efforts to better meet 21st century data needs.
23m listen
